CA3072240A1 - Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione - Google Patents

Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione Download PDF

Info

Publication number
CA3072240A1
CA3072240A1 CA3072240A CA3072240A CA3072240A1 CA 3072240 A1 CA3072240 A1 CA 3072240A1 CA 3072240 A CA3072240 A CA 3072240A CA 3072240 A CA3072240 A CA 3072240A CA 3072240 A1 CA3072240 A1 CA 3072240A1
Authority
CA
Canada
Prior art keywords
ing
solvate
solid form
degrees
theta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3072240A
Other languages
English (en)
French (fr)
Inventor
Yamin ZHANG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Actuate Therapeutics Inc
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63405430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3072240(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of CA3072240A1 publication Critical patent/CA3072240A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
CA3072240A 2017-08-11 2018-08-10 Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione Pending CA3072240A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
US62/544,277 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE

Publications (1)

Publication Number Publication Date
CA3072240A1 true CA3072240A1 (en) 2019-02-14

Family

ID=63405430

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3072240A Pending CA3072240A1 (en) 2017-08-11 2018-08-10 Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5h-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione

Country Status (16)

Country Link
US (3) US11136334B2 (https=)
EP (1) EP3665176B1 (https=)
JP (3) JP7424639B2 (https=)
KR (3) KR102700883B1 (https=)
CN (2) CN117362305A (https=)
AU (3) AU2018313259B2 (https=)
BR (1) BR112020002892A2 (https=)
CA (1) CA3072240A1 (https=)
DK (1) DK3665176T3 (https=)
ES (1) ES2974328T3 (https=)
FI (1) FI3665176T3 (https=)
IL (2) IL272556B2 (https=)
MX (3) MX2020001547A (https=)
PL (1) PL3665176T3 (https=)
PT (1) PT3665176T (https=)
WO (1) WO2019032958A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3697794T3 (pl) 2017-10-16 2026-04-07 Actuate Therapeutics Inc. Stałe postacie 3-(5-fluorobenzofuran-3-ylo)-4-(5-metylo-5h-[1,3]dioksolo[4,5-f]indol-7-ilo)pirolo-2,5-dionu
WO2019222483A1 (en) * 2018-05-17 2019-11-21 Board Of Regents, The University Of Texas System Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
US20250325517A1 (en) * 2022-06-27 2025-10-23 Actuate Therapeutics, Inc. Oral dosage forms of elraglusib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
PH12012501293A1 (en) 2009-12-23 2013-01-07 Arqule Inc Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Also Published As

Publication number Publication date
CN117362305A (zh) 2024-01-09
MX2020001547A (es) 2020-08-03
ES2974328T3 (es) 2024-06-26
PL3665176T3 (pl) 2024-06-17
JP7778750B2 (ja) 2025-12-02
IL313800A (en) 2024-08-01
BR112020002892A2 (pt) 2020-08-04
KR102700883B1 (ko) 2024-09-02
JP2023156372A (ja) 2023-10-24
KR20240063198A (ko) 2024-05-09
KR20250070131A (ko) 2025-05-20
AU2025202936A1 (en) 2025-05-15
CN111247153B (zh) 2024-04-02
US20220009939A1 (en) 2022-01-13
MX2024003249A (es) 2024-04-04
IL272556B1 (en) 2024-09-01
AU2023201059A1 (en) 2023-03-23
EP3665176A1 (en) 2020-06-17
DK3665176T3 (da) 2024-03-25
JP2020530497A (ja) 2020-10-22
US20250115616A1 (en) 2025-04-10
US20200223861A1 (en) 2020-07-16
WO2019032958A1 (en) 2019-02-14
US11136334B2 (en) 2021-10-05
AU2018313259B2 (en) 2022-11-24
AU2023201059B2 (en) 2025-04-03
PT3665176T (pt) 2024-03-13
AU2018313259A1 (en) 2020-02-27
EP3665176B1 (en) 2024-01-24
US12145943B2 (en) 2024-11-19
KR20200040799A (ko) 2020-04-20
FI3665176T3 (fi) 2024-03-20
IL272556A (en) 2020-03-31
MX2023005875A (es) 2023-06-05
CN111247153A (zh) 2020-06-05
JP7424639B2 (ja) 2024-01-30
JP2026012715A (ja) 2026-01-27
IL272556B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
AU2023201059B2 (en) Solid forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
US20250115615A1 (en) Solid Forms of 3-(5-Fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
HK40106022A (zh) 9-ing-41的固体形式
BR112020007538B1 (pt) Forma sólida, processo para preparar a forma sólida, composição farmacêutica, processo para preparar a composição farmacêutica e uso da forma sólida

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230802

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240802

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240802

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240802

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20241002

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250203

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250221

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250703

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250703

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250728

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250728

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250730

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251128

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260112

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260112

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260112